About |
ScionxBio, formerly Eleven Therapeutics, is a Cambridge-based preclinical biotechnology company developing long-acting, programmable xRNA therapeutics for cardio-metabolic disease. The company’s TERÅ® platform applies combinatorial chemistry and deep learning to engineer RNA molecules with exceptional stability and sustained protein expression, enabling infrequent dosing and consistent therapeutic effect. ScionxBio emerged from stealth, having operated independently since January 2026 following the completion of a horizontal split by Eleven Therapeutics, with a focused mission to develop next-generation xRNA therapeutics for cardio-metabolic disease.